Takeda Pharma - Bathi resik saben saham (EPS TTM) TAK

Simbol resmi perusahaan Takeda (TAK)

Financial pressure from debt and patents impacts expenses, which is why the trailing twelve-month net income per share from GURU.Markets is used for analysis, where 0.06 shows the current value of the metric. Takeda Pharmaceutical (TAK) bases its business efficiency on robotic production, while the stability of this veteran Japanese behemoth is ensured by a strong workforce and a focus on R&D.

TAK (Takeda Pharmaceutical) riwayat Bathi resik saben saham sajrone patang kuartal pungkasan saka 04.07.2022 nganti 16.11.2026

Rincian analitis perusahaan Takeda Pharmaceutical

- kuotasi saiki lan rata-rata prakiraan nilai:
- rincian nilai pasar emiten:
Ringkesan analitik perusahaan:takeda.com (TAK)
Produk sing diprodhuksi Takeda Pharma

The TTM EPS metric aggregates net income over the last four quarters, allocating it per share to eliminate distortions from issuance. For Takeda Pharmaceutical (TAK), a leader in rare disease therapy, the company's trailing 12-month earnings per share reflect the efficiency of innovation capitalization, helping investors determine whether the current stock value is justified or indicates a risk of overpayment.